CVRX

Company Overview — What Does CVRx, Inc. Do?

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. CVRx, Inc. (CVRX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Nadim Yared and employs approximately 160 people. With a market capitalization of $239M, CVRX is one of the notable companies in the Healthcare sector.

CVRx, Inc. (CVRX) Stock Rating — Reduce (April 2026)

As of April 2026, CVRx, Inc. receives a Reduce rating with a composite score of 28.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CVRX ranks #2,771 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CVRx, Inc. ranks #379 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CVRX Stock Price and 52-Week Range

CVRx, Inc. (CVRX) currently trades at $7.16. The stock lost $0.33 (4.3%) in the most recent trading session. The 52-week high for CVRX is $13.34, which means the stock is currently trading -46.4% from its annual peak. The 52-week low is $4.30, putting the stock 66.4% above its annual trough. Recent trading volume was 492K shares, suggesting relatively thin trading activity.

Is CVRX Overvalued or Undervalued? — Valuation Analysis

CVRx, Inc. (CVRX) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.60x, versus the sector average of 2.75x. The price-to-sales ratio is 4.08x, compared to 1.66x for the average Healthcare stock.

At current multiples, CVRx, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CVRx, Inc. Profitability — ROE, Margins, and Quality Score

CVRx, Inc. (CVRX) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -138.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -52.0% versus the sector average of -33.1%.

On a margin basis, CVRx, Inc. reports gross margins of 84.4%, compared to 71.5% for the sector. The operating margin is -98.9% (sector: -66.1%). Net profit margin stands at -101.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 24.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CVRX Debt, Balance Sheet, and Financial Health

CVRx, Inc. has a debt-to-equity ratio of 166.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 7.63x, indicating strong short-term liquidity. Total debt on the balance sheet is $49M. Cash and equivalents stand at $85M.

CVRX has a beta of 1.72, meaning it is more volatile than the broader market — a $10,000 investment in CVRX would be expected to move 71.8% more than the S&P 500 on any given day. The stability factor score for CVRx, Inc. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CVRx, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, CVRx, Inc. reported revenue of $54M and earnings per share (EPS) of $-2.04. Net income for the quarter was $-54M. Gross margin was 84.4%. Operating income came in at $-53M.

In FY 2025, CVRx, Inc. reported revenue of $57M and earnings per share (EPS) of $-2.04. Net income for the quarter was $-53M. Gross margin was 85.3%. Revenue grew 10.4% year-over-year compared to FY 2024. Operating income came in at $-51M.

In Q3 2025, CVRx, Inc. reported revenue of $15M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-13M. Gross margin was 86.8%. Revenue grew 9.8% year-over-year compared to Q3 2024. Operating income came in at $-12M.

In Q2 2025, CVRx, Inc. reported revenue of $14M and earnings per share (EPS) of $-0.57. Net income for the quarter was $-15M. Gross margin was 84.3%. Revenue grew 15.1% year-over-year compared to Q2 2024. Operating income came in at $-14M.

Over the past 8 quarters, CVRx, Inc. has demonstrated a growth trajectory, with revenue expanding from $12M to $54M. Investors analyzing CVRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CVRX Dividend Yield and Income Analysis

CVRx, Inc. (CVRX) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CVRX Momentum and Technical Analysis Profile

CVRx, Inc. (CVRX) has a momentum factor score of 37/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 44/100 reflects moderate short selling activity.

CVRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CVRx, Inc. (CVRX) ranks #379 out of 838 stocks based on the Blank Capital composite score. This places CVRX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CVRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CVRX vs S&P 500 (SPY) comparison to assess how CVRx, Inc. stacks up against the broader market across all factor dimensions.

CVRX Next Earnings Date

No upcoming earnings date has been announced for CVRx, Inc. (CVRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CVRX? — Investment Thesis Summary

The quantitative profile for CVRx, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. Momentum is weak at 37/100, a headwind for near-term performance. High volatility (stability score 22/100) increases portfolio risk.

In summary, CVRx, Inc. (CVRX) earns a Reduce rating with a composite score of 28.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CVRX stock.

Related Resources for CVRX Investors

Explore more research and tools: CVRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CVRX head-to-head with peers: CVRX vs AZN, CVRX vs SLGL, CVRX vs VMD.